Morgan Stanley Rhythm Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 524,480 shares of RYTM stock, worth $56.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

524,480

Previous 504,049 4.05%

Holding current value

$56.2 Million

Previous $26.7 Million 24.13%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$46.95 - $68.11 $959,235 - $1.39 Million	20,431 Added 4.05%	524,480 $33.1 Million
Q1 2025 May 15, 2025	SELL	$48.56 - $61.02 $2.72 Million - $3.42 Million	-56,038 Reduced 10.01%	504,049 $26.7 Million
Q4 2024 Feb 14, 2025	BUY	$46.91 - $67.33 $4.48 Million - $6.43 Million	95,483 Added 20.55%	560,087 $31.3 Million
Q3 2024 May 14, 2025	SELL	$40.81 - $55.0 $450,828 - $607,585	-11,047 Reduced 2.32%	464,604 $24.3 Million
Q3 2024 Nov 14, 2024	SELL	$40.81 - $55.0 $450,828 - $607,585	-11,047 Reduced 2.32%	464,604 $24.3 Million
Q2 2024 May 14, 2025	SELL	$35.41 - $44.37 $2.99 Million - $3.75 Million	-84,436 Reduced 15.08%	475,651 $19.5 Million
Q2 2024 Oct 17, 2024	BUY	$35.41 - $44.37 $10.4 Million - $13 Million	292,781 Added 160.1%	475,651 $19.5 Million
Q2 2024 Aug 14, 2024	BUY	$35.41 - $44.37 $10.4 Million - $13 Million	292,781 Added 160.1%	475,651 $19.5 Million
Q1 2024 Oct 17, 2024	SELL	$39.12 - $52.44 $11.5 Million - $15.4 Million	-292,781 Reduced 61.55%	182,870 $7.92 Million
Q1 2024 Aug 16, 2024	SELL	$39.12 - $52.44 $1.91 Million - $2.56 Million	-48,786 Reduced 21.06%	182,870 $7.92 Million
Q1 2024 May 15, 2024	SELL	$39.12 - $52.44 $1.91 Million - $2.56 Million	-48,786 Reduced 21.06%	182,870 $7.92 Million
Q4 2023 Aug 16, 2024	SELL	$21.39 - $49.64 $5.22 Million - $12.1 Million	-243,995 Reduced 51.3%	231,656 $10.6 Million
Q4 2023 Feb 13, 2024	SELL	$21.39 - $49.64 $4.38 Million - $10.2 Million	-204,752 Reduced 46.92%	231,656 $10.6 Million
Q3 2023 Nov 15, 2023	BUY	$15.81 - $27.8 $5.27 Million - $9.26 Million	333,227 Added 322.95%	436,408 $10 Million
Q2 2023 Aug 14, 2023	SELL	$16.32 - $21.15 $1.85 Million - $2.4 Million	-113,440 Reduced 52.37%	103,181 $1.7 Million
Q1 2023 May 15, 2023	SELL	$16.88 - $34.24 $456,840 - $926,671	-27,064 Reduced 11.11%	216,621 $3.86 Million
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $299,568 - $408,012	13,488 Added 5.86%	243,685 $7.1 Million
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $862,365 - $6.19 Million	-200,550 Reduced 46.56%	230,197 $5.64 Million
Q2 2022 Oct 27, 2022	BUY	$3.12 - $12.25 $546,795 - $2.15 Million	175,255 Added 68.6%	430,747 $1.79 Million
Q2 2022 Aug 15, 2022	BUY	$3.12 - $12.25 $546,795 - $2.15 Million	175,255 Added 68.6%	430,747 $1.79 Million
Q1 2022 Oct 27, 2022	SELL	$6.13 - $12.24 $1.07 Million - $2.15 Million	-175,255 Reduced 40.69%	255,492 $2.94 Million
Q1 2022 May 13, 2022	SELL	$6.13 - $12.24 $78,899 - $157,541	-12,871 Reduced 4.8%	255,492 $2.94 Million
Q4 2021 Feb 14, 2022	BUY	$8.62 - $13.9 $542,172 - $874,268	62,897 Added 30.61%	268,363 $2.68 Million
Q3 2021 Nov 15, 2021	BUY	$11.68 - $20.72 $2.4 Million - $4.26 Million	205,466 New	205,466 $2.68 Million

Others Institutions Holding RYTM

# of Institutions

250

Shares Held

63.9M

Call Options Held

210K

Put Options Held

575K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $5.97B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account